Day: March 13, 2024

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced the launch of Enhanced Search. This new cutting-edge search functionality, available on both Getty Images and iStock’s platforms, is built to redefine how customers find and discover visual content by delivering faster and more relevant results through natural and conversational queries to elevate their creative process. Powered by innovative AI and machine learning models, Enhanced Search enables users to explore Getty Images’ and iStock’s extensive library of pre-shot creative content of millions of images, videos, and illustrations with an increased level of detail. The new functionality...

SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) — ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical’s presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024. The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay. About ICU Medical ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion...

Following highest annual revenue in Company history, and $3.5 million in bank financing, Company anticipates achieving Adjusted EBITDA positive by 2H 2024   Scottsdale, Ariz., March 13, 2024 (GLOBE NEWSWIRE) — CISO Global (NASDAQCM: CISO), an industry leader as a managed cybersecurity, compliance and proprietary software provider, is announcing preliminary estimated financial information as of and for the fiscal year ending December 31, 2023. These estimated results are being announced ahead of the filing of the Company’s Form 10-K, which will be filed by April 16, 2024. Highlights include:$57.1 million in estimated total revenue for the fiscal year ending December 31, 2023, an increase of $10.5 million, or 23%, compared to total revenue of $46.5 million for the fiscal year ending December 31, 2022 ($13.8) million in estimated...

Summary: Leading public safety technology company, SoundThinking, Inc. today announced a combined 7 new contracts and expansions for the deployment of ShotSpotter, the industry-leading gunshot detection system, further solidifying ShotSpotter’s presence across key metropolitan regions. FREMONT, Calif., March 13, 2024 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI) (formerly ShotSpotter, Inc.), a leading public safety technology company, today announced a total of 7 new customers and expanded coverage areas for its flagship ShotSpotter gunshot detection system. In the first quarter of 2024, the company secured multiple agreements with municipalities implementing ShotSpotter for the first time or significantly increasing their existing coverage areas, while other cities also went live with newly deployed ShotSpotter technology. One...

COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older. The approval represents the first national marketing authorization issued to Bavarian Nordic since 2019 and was facilitated by the Swiss authorities in response to the 2022 global mpox outbreak. During the outbreak, Bavarian Nordic supplied its mpox vaccine under emergency use provisions to countries where the vaccine was not approved, and which previously had not stockpiled the vaccine. In Switzerland, Bavarian Nordic committed to seeking marketing authorization of the vaccine and thus initiated the submission of its application in late December...

BranchOut Food is pleased to be innovating in a new category with our salad topper lineBranchOut Food to Debut New Products at Natural Products Expo WestBranchOut Food’s new kids’ snack packs are perfect for school lunches and include chewy banana, pineapple chips, carrot sticks and bell pepper crispsBranchOut Food Snack Pack LineNatural Products Expo West showcases trending products for retailers stocking stores shelves nationwide BranchOut Food will launch two new products lines including Salad Toppers and Kids’ Snack Packs     BEND, Ore., March 13, 2024 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a pioneering food technology company and producer of dehydrated fruit and vegetable-based products, today announced that it will debut a brand refresh and launch two new product lines at its exhibit at the...

  New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active traffic at the Company’s booth generated a record-high number of sales leads and affirms very strong interest in a better economic choice BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the successful launch of its new “Fair Deal Agreement” for the SRT-100 Vision™ (IG-SRT) at the AAD 2024 Annual Meeting, held March 8-12 in San Diego. This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event. Under...

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024 Released long-term data from the open-label extension of the HEALEY ALS Platform Trial in which CNM-Au8 demonstrated statistically significant reductions of plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023) as well as a 60% decreased risk of long-term all-cause mortality using rank-preserving structural failure time model analysis (>18 months, p=0.0167) Demonstrated a statistically significant survival benefit (p=0.0001) in Expanded Access Program (EAP) participants (n=220) treated with CNM-Au8 compared to historical ALS disease progression controls with decreased risk of all-cause mortality ranging from 57%-68% Reported...